Maximizing Outcomes in Relapsed/Refractory Multiple Myeloma: Tailoring Bispecific Antibody Approaches : Episode 6
MagnestisMM: Key Efficacy Data and its Clinical Implications
In this segment, Dr. Mohan asks Dr. Mann to summarize the key efficacy data from the MagnestisMM trials evaluating the use of elranatamab in relapsed/refractory multiple myeloma (R/R MM).
Video Player is loading.
EP: 1.John’s Journey with R/R MM
EP: 2.MonumenTAL: Key Efficacy Outcomes
EP: 3.Implications of Talquetamab on the Current Treatment Landscape for R/R MM
EP: 4.Bispecifics in R/R MM: Selecting the Best Bispecific and Optimal Sequencing Strategies
EP: 5.Eva’s Treatment Journey With R/R MM
Now Viewing
EP: 6.MagnestisMM: Key Efficacy Data and its Clinical Implications
EP: 7.Elranatamab: Real-World Experience and Sequencing
EP: 8.Future of R/R MM: Emerging Agents
Video content above is prompted by the following:
Can you summarize the key efficacy data from the MagnestisMM trials evaluating the use of elranatamab in R/R MM?
Recent Videos
Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer
Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer
Second-Line Treatment for Gastric Adenocarcinoma
Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches
Gastric Adenocarcinoma: Current Treatment Landscape
Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW
Esophageal/Gastric Adenocarcinoma Standard of Care
BESPOKE: Study Design, Efficacy End Points and Methods
Related Content
